Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Investor Presentation (December 2018)
26 slides from Anatara Lifesciences's investor presentation, Dec 6, 2018
Slide 1: Bringing Science to Supplements
For personal use only Bringing Science to Supplements December 2018
Slide 2: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 3: Key Investor Message
Key Investor Message For personal use only Anatara Lifesciences (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. 3
Slide 4: Anatara Corporate History
Anatara Corporate History Global License with Zoetis for Detach for livestock and horses Zoetis Option For personal use only Human Health Directors Appointed – Dr Jane Ryan & Expand Management Team Sue MacLeman, Chair Melbourne lab established Product Development Advisory Board established ASX Listi
Slide 5: Key Management & Board of Directors
Key Management & Board of Directors For personal use only Steve Lydeamore, CEO Sue MacLeman, Chair • 25+ years international pharmaceutical • 30+ years pharmaceutical, biotechnology and experience in Australia, USA and Canada medical technology experience in corporate, • Lead roles in global busines
Slide 6: Key Financial Details
Key Financial Details For personal use only ASX Code Market Share Price1 Capitalisation1 ANR $22.2 million $0.45 Current Cash2 Ordinary Shares Options $7.1 million 49,413,236 2,346,000 1. As at 30 November 2018 2. Appendix 4C - 30 September 2018 6
Slide 7: Company Highlights
Company Highlights For personal use only • Negotiated an exclusive global licensing agreement for the worldwide development, distribution and marketing of Detach with Zoetis Inc - leading global animal health company • Detach received regulatory approval from Australian Pesticides and Veterinary Med
Slide 8: Company Highlights Cont.
Company Highlights Cont. For personal use only • Human development program well underway - developing scientifically innovative and commercially attractive products for gastrointestinal health in areas of critical need • First product candidate - Gastrointestinal ReProgramming (GaRP) dietary supplem
Slide 9: Animal Health
Animal Health For personal use only • Detach is a natural, safe, non-antibiotic product that aids in the control of diarrhoea (known as scour) in livestock • In May 2018, Anatara signed an exclusive licensing agreement with Zoetis Inc., the leading global animal health company, for the worldwide dev
Slide 10: From animals to humans
For personal use only From animals to humans
Slide 11: Anatara's Technology
Anatara’s Technology For personal use only • Bromelain is a natural product extracted from pineapple stems. • Based on decades of research by world- class academic and commercial partners which found that bromelain contains a number of proteases with distinct biological activities, including • Anti-
Slide 12: About Irritable Bowel Syndrome (IBS)
About Irritable Bowel Syndrome (IBS) • IBS is a functional disorder. For personal use only Incomplete knowledge of pathology, therefore the approach is symptom management • Symptoms include abdominal pain, bloating and alternating constipation and diarrhoea • Patients have a poor quality of Affects
Slide 13: About Inflammatory Bowel Disease (IBD)
About Inflammatory Bowel Disease (IBD) For personal use only • Two forms: Ulcerative Colitis and Crohn’s Disease • Patients experience abdominal pain and cramping, bloating, blood and mucus in the stool, loss of appetite and persistent diarrhoea >5m • Treatment involves suppressing IBD sufferers inf
Slide 14: Gastrointestinal ReProgramming (GaRP) Dietary Supplement
Anatara has designed a For personal use only novel product aimed at restoring and maintaining gut health: Gastrointestinal ReProgramming (GaRP) Dietary Supplement For the Management of Gastrointestinal Disorders 14
Slide 15: Target Gastrointestinal Disorders
Target Gastrointestinal Disorders For personal use only Irritable Bowel Syndrome (IBS) Inflammatory Bowel Disease (IBD) Affects around 11% of the global population1 >5 million sufferers globally2 Low grade inflammation Chronic inflammation Shared disease characteristics: Altered microbiome Impaired
Slide 16: The Microbiome and IBS/IBD
The Microbiome and IBS/IBD For personal use only Healthy gut microbiome • Supplies energy and nutrients • Immune system development • Defence against pathogens Healthy gut – increased diversity IBD/IBS gut microbiome • Less bacteria with anti-inflammatory properties • More bacteria with pro-inflamma
Slide 17: How GaRP works
How GaRP works For personal use only GaRP GaRPwill is abemicrobiome-targeted a microbiome-centric complementary medicine*aimed dietary supplement aimed at: at: Correcting Alleviation of gut Repair of gut the microbiota Reduction of lining and symptomatic to restore inflammation barrier diarrhoea nor
Slide 18: Dietary Supplements as an adjunct to prescription drugs
Dietary Supplements as an For personal use only adjunct to prescription drugs for the treatment of GI disorders • ~50% of patients seek additional relief of their symptoms through adjunct therapies • Increased education and more detailed evaluation of dietary supplements has led to health-care provi
Slide 19: GaRP – built on strong scientific foundations
For personal use only GaRP – built on strong scientific foundations 19
Slide 20: About Bromelain
About Bromelain For personal use only Generally Recognised Unlimited Acceptable But formal clinical as Safe (GRAS) Daily Intake (ADI) data has been lacking Bromelain is allowed in food as a Bromelain has been used for A lot of anecdotal evidence food additive and it has been decades in as an anti-in
Slide 21: Dual targeted product combining bromelain and other GRAS components
Dual targeted product combining bromelain and other GRAS components* For personal use only Ileum targeted components • prevent attachment of pro-inflammatory bacteria • restore gut microbiota • reduce inflammation Colon targeted components • restore gut microbiota Ileum • reduce inflammation • mucos
Slide 22: GaRP Development Plan
GaRP Development Plan For personal use only • Commercial Feasibility - confirming the clinical and market need for a multi-functional dietary supplement that could act as an adjunct to current IBD and IBS medications. • Proof of concept studies are well advanced to demonstrate that GaRP can: • Remov
Slide 23: Regulatory Advantages of Dietary Supplements
Regulatory Advantages of Dietary Supplements* For personal use only The advantages of a dietary supplement regulatory strategy are: 1. Less expensive and less risky pathway to market 2. Rapid market entry 3. Public and health care professionals understand the term ‘dietary supplement’ 4. Marketing c
Slide 24: A Clear Path to Commercialisation
A Clear Path to Commercialisation For personal use only 2017 2017 2018 2018 2019 2019 2020 2020 H1 H2 H1 H2 H1 H2 H1 H2 Confirmed GRAS status for ✓ components with FDA Established collaboration with ✓ University of Liverpool (UK) Completed product development ✓ plan Patent Application filed ✓ Commer
Slide 25: Product Development Advisory Board
Product Development Advisory Board For personal use only Professor Peter Gibson Dr Rebecca Burgell Dr Jakob Begun Professor Barry Campbell Professor Simon Keely • Advisory Board members are internationally recognised for their expertise in IBS and IBD with experience ranging from preclinical drug de
Slide 26: Thank you
For personal use only Thank you
Anatara Lifesciences — Investor Presentation (December 2018) on 6ix